Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2, 2010, Pages

  Kelly, Margaret M ^a,b   O'Connor, Terence M ^a   Leigh, Richard ^a,b   Otis, Joceline ^a   Gwozd, Carol ^b   Gauvreau, Gail M ^a   Gauldie, Jack ^a   O'Byrne, Paul M ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

biopsy; Bronchial provocation tests; bronchoscopy; inhaled glucocorticoids; long acting inhaled agonists

Indexed keywords

ALLERGEN; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; PLACEBO; SYMBICORT TURBUHALER; UNCLASSIFIED DRUG;

ADULT; AIRWAY DYNAMICS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EOSINOPHILIA; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MONOTHERAPY; MYOFIBROBLAST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE; SPUTUM; SUBMUCOSA;

EID: 75849142853     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.011     Document Type: Article

References (51)

1. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008) 143-178
2. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary Report 2007. J Allergy Clin Immunol 120 suppl (2007) S94-S138
3. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
4. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
5. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
6. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
7. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
8. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
9. Juniper E.F., Svensson K., O'Byrne P.M., Barnes P.J., Bauer C.A., Lofdahl C.G., et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 14 (1999) 1038-1043
10. Bateman E.D., Jacques L., Goldfrad C., Atienza T., Mihaescu T., and Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 117 (2006) 563-570
11. Sears M.R., Boulet L.P., Laviolette M., FitzGerald J.M., Bai T.R., Kaplan A., et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 31 (2008) 982-989
12. Cockcroft D.W. Airway responsiveness. In: Barnes P.J., Grunstein M.M., Leff A.R., and Woolcock A.J. (Eds). Asthma (1997), Lippencott-Raven, Philadelphia 1253-1266
13. Gauvreau G.M., Doctor J., Watson R.M., Jordana M., and O'Byrne P.M. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 154 (1996) 1267-1271
14. Leigh R., Vethanayagam D., Yoshida M., Watson R.M., Rerecich T., Inman M.D., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 166 (2002) 1212-1217
15. Wiggs B.R., Bosken C., Pare P.D., James A., and Hogg J.C. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 145 (1992) 1251-1258
16. Bousquet J., Jeffery P.K., Busse W.B., Johnson M., and Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161 (2000) 1720-1745
17. James A.L., and Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 30 (2007) 134-155
18. Bates J.H., Cojocaru A., Haverkamp H.C., Rinaldi L.M., and Irvin C.G. The synergistic interactions of allergic lung inflammation and intratracheal cationic protein. Am J Respir Crit Care Med 177 (2008) 261-268
19. O'Byrne P. Asthma pathogenesis and allergen-induced late responses. J Allergy Clin Immunol 102 suppl (1998) S85-S89
20. Gizycki M.J., Adelroth E., Rogers A., O'Byrne P., and Jeffery P.K. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 16 (1997) 664-673
21. Schurch W., Seemayer T.A., and Gabbiani G. The myofibroblast: a quarter century after its discovery. Am J Surg Pathol 22 (1998) 141-147
22. Kariyawasam H.H., Aizen M., Barkans J., Robinson D.S., and Kay A.B. Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma. Am J Respir Crit Care Med 175 (2007) 896-904
23. O'Connor T.M., Kelly M.M., Leigh R., Otis J., Gauvreau G.M., Gauldie J., et al. Anti-inflammatory effects of inhaled budesonide combined with formoterol after allergen challenge in subjects with atopic asthma. [abstract]. Am J Respir Crit Care Med 3 (2006) A75
24. O'Connor T.M., Kelly M.M., Leigh R., Otis J., Gauvreau G.M., Gauldie J., et al. Additional anti-inflammatory effects of inhaled budesonide/formoterol over inhaled budesonide in subjects with atopic asthma. [abstract]. Eur Respir J 28 (2006) 441S
25. Kelly M.M., O'Connor T.M., Leigh R., Otis J., Gauvreau G.M., Gauldie J., et al. Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myofibroblasts. [abstract]. Eur Respir J 30 (2008) P903
26. Kelly M.M., Chakir J., Vethanayagam D., Boulet L.P., Laviolette M., Gauldie J., et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130 (2006) 741-753
27. Juniper E.F., Frith P.A., Dunnett C., Cockcroft D.W., and Hargreave F.E. Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax 33 (1978) 705-710
28. Giembycz M.A., Kaur M., Leigh R., and Newton R. A holy grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 153 (2008) 1090-1104
29. McIvor R.A., Pizzichini E., Turner M.O., Hussack P., Hargreave F.E., and Sears M.R. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158 (1998) 924-930
30. Roberts J.A., Bradding P., Britten K.M., Walls A.F., Wilson S., Gratziou C., et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 14 (1999) 275-282
31. Duong M., Gauvreau G., Watson R., Obminski G., Strinich T., Evans M., et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 119 (2007) 322-327
32. Li X., Ward C., Thien F., Bish R., Bamford T., Bao X., et al. An antiiinflammatory effect of salmeterol, a long-acting beta2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160 (1999) 1493-1499
33. Baouz S., Giron-Michel J., Azzarone B., Giuliani M., Cagnoni F., Olsson S., et al. Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol 17 (2005) 1473-1481
34. Kaur M., Chivers J.E., Giembycz M.A., and Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 73 (2008) 203-214
35. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164 suppl (2001) S28-S38
36. Pare P.D., Wiggs B.R., James A., Hogg J.C., and Bosken C. The comparative mechanics and morphology of airways in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 143 (1991) 1189-1193
37. Carroll N., Elliot J., Morton A., and James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 147 (1993) 405-410
38. Woodruff P.G., Dolganov G.M., Ferrando R.E., Donnelly S., Hays S.R., Solberg O.D., et al. Hyperplasia of smooth muscle in mild/moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 169 (2004) 1001-1006
39. Katoh K., Kano Y., Amano M., Onishi H., Kaibuchi K., and Fujiwara K. Rho-kinase-mediated contraction of isolated stress fibers. J Cell Biol 153 (2001) 569-584
40. Bogatkevich G.S., Tourkina E., Abrams C.S., Harley R.A., Silver R.M., and Ludwicka-Bradley A. Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am J Physiol Lung Cell Mol Physiol 285 (2003) L334-L343
41. Ward C., and Walters H. Airway wall remodelling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol 5 (2005) 43-48
42. Benayoun L., Druilhe A., Dombret M.C., Aubier M., and Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 167 (2003) 1360-1368
43. Madison J.M. Migration of airway smooth muscle cells. Am J Respir Cell Mol Biol 29 (2003) 8-11
44. Roth M., Johnson P.R., Borger P., Bihl M.P., Rudiger J.J., King G.G., et al. Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med 351 (2004) 560-574
45. Bonacci J.V., Harris T., Wilson J.W., and Stewart A.G. Collagen-induced resistance to glucocorticoid anti-mitogenic actions: a potential explanation of smooth muscle hyperplasia in the asthmatic remodelled airway. Br J Pharmacol 138 (2003) 1203-1206
46. Pepe C., Foley S., Shannon J., Lemiere C., Olivenstein R., Ernst P., et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 116 (2005) 544-549
47. Moreno R.H., Hogg J.C., and Pare P.D. Mechanics of airway narrowing. Am Rev Respir Dis 133 (1986) 1171-1180
48. James A.L., Pare P.D., and Hogg J.C. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 139 (1989) 242-246
49. Wiggs B.R., Moreno R., Hogg J.C., Hilliam C., and Pare P.D. A model of the mechanics of airway narrowing. J Appl Physiol 69 (1990) 849-860
50. Lambert R.K., Wiggs B.R., Kuwano K., Hogg J.C., and Pare P.D. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol 74 (1993) 2771-2781
51. Kuwano K., Bosken C.H., Pare P.D., Bai T.R., Wiggs B.R., and Hogg J.C. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 148 (1993) 1220-1225